Medshape, Inc. v. Arthrex, Inc.

CourtDistrict Court, W.D. Texas
DecidedAugust 29, 2025
Docket6:24-cv-00151
StatusUnknown

This text of Medshape, Inc. v. Arthrex, Inc. (Medshape, Inc. v. Arthrex, Inc.) is published on Counsel Stack Legal Research, covering District Court, W.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Medshape, Inc. v. Arthrex, Inc., (W.D. Tex. 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS WACO DIVISION

MEDSHAPE, INC., TRILLIANT § SURGICAL LLC, (d/b/a ENOVIS FOOT § § AND ANKLE), and ENCORE § MEDICAL, L.P., § § Plaintiffs, § § Case No. 6:24-cv-00151-DTG v. § § § ARTHREX, INC. and ARTHREX § MANUFACTURING, INC. § § Defendants. §

CLAIM CONSTRUCTION ORDER

Pending before the Court is a claim construction dispute involving two terms from a single patent. The parties fully briefed their positions, the Court provided preliminary constructions, and the Court held a claim construction hearing on December 5, 2024. After hearing arguments of counsel, the Court took the construction of one term, “bone fragment,” under advisement and confirmed that its preliminary construction of the “substantially in an austenitic phase” terms would be adopted as the final construction. Dkt. No. 64 at 55:5-17. This order provides final constructions for both terms as follows. After the claim construction hearing, an additional dispute arose over whether the steps of claim 1 must be performed in a specific order. The defendant, Arthrex, Inc., moved for an additional claim construction to resolve this dispute. Dkt. No. 68. That motion was opposed and has been fully briefed, including a sur-reply. Dkt. Nos. 79, 81, 88. The Court finds a hearing on this additional dispute unnecessary and GRANTS this additional motion (Dkt. No. 68) for the reasons that follow. I. CLAIM CONSTRUCTION Claim construction starts with the general rule that claim terms are construed according to their ordinary meaning as understood by a person of skill in the relevant art. Phillips v. AWH Corp., 415 F.3d 1303, 1312-13 (Fed. Cir. 2005) (en banc); Alloc, Inc. v. Int’l Trade Comm’n, 342 F.3d 1361, 1368 (Fed. Cir. 2003); Azure Networks, LLC v. CSR PLC, 771 F.3d 1336, 1347

(Fed. Cir. 2014) (holding that there is a heavy presumption in favor of the ordinary meaning) cert. granted, judgment vacated, 135 S. Ct. 1846 (2015). To determine the construction, courts start by considering the intrinsic evidence, which includes the claims, specification, and prosecution history. Phillips, 415 F.3d at 1313-14. Extrinsic evidence—such as technical dictionaries, treatises, and expert testimony—can also be useful, but it is given less weight than the intrinsic evidence. Phillips, 415 F.3d at 1317-18 (quoting C.R. Bard, Inc., 388 F.3d at 862). There are two exceptions to the general rule in favor of ordinary meaning. These exceptions are “1) when a patentee sets out a definition and acts as his own lexicographer, or 2) when the patentee disavows the full scope of the claim term either in the specification or during

prosecution.” Golden Bridge Tech., Inc. v. Apple Inc., 758 F.3d 1362, 1365 (Fed. Cir. 2014) (quoting Thorner v. Sony Comput. Entm’t Am. LLC, 669 F.3d 1362, 1365 (Fed. Cir. 2012)); see also GE Lighting Sols., LLC v. AgiLight, Inc., 750 F.3d 1304, 1309 (Fed. Cir. 2014) (“[T]he specification and prosecution history only compel departure from the plain meaning in two instances: lexicography and disavowal.”). The standards for finding lexicography or disavowal are “exacting” with both requiring clear evidence. GE Lighting Sols., 750 F.3d at 1309. Proving disavowal requires clear and unmistakable evidence. Golden Bridge Tech., Inc., 758 F.3d at 1365. Patent claims must also particularly point out and distinctly claim the subject matter regarded as the invention. 35 U.S.C. § 112, ¶ 2. A claim, when viewed in light of the intrinsic evidence, must “inform those skilled in the art about the scope of the invention with reasonable certainty.” Nautilus Inc. v. Biosig Instruments, Inc., 572 U.S. 898, 910 (2014). If it does not, the claim fails § 112, ¶ 2 and is invalid as indefinite. Id. at 901. Whether a claim is indefinite is

determined from the perspective of one of ordinary skill in the art as of the time the application for the patent was filed. Id. at 911. As it is a challenge to the validity of a patent, proof of indefiniteness must be shown by clear and convincing evidence. BASF Corp. v. Johnson Matthey Inc., 875 F.3d 1360, 1365 (Fed. Cir. 2017). II. BACKGROUND This patent infringement case involves two asserted patents. One asserted patent is U.S. Patent No. 7,985,222, which is titled, “Osteosynthetic Implants and Methods of Use and Manufacture.” Dkt. No. 35-1. The other asserted patent is U.S. Patent No. 8,491,583, which is titled, “Intramedullary Medical Device and Methods of Use and Manufacture.” Dkt. No. 35-2.

All of the claim construction disputes involve the ’222 Patent. That patent covers an invention for “bone fracture fixation devices, systems and methods of use and manufacture.” Dkt. No. 35-1 at 2 (“ABSTRACT”). The ’222 Patent contains one independent claim, which reads as follows: 1. A method, comprising: (a) inserting a bone device having a longitudinal axis into a first bone fragment and a second bone fragment, wherein the inserting causes a first portion of the bone device to contact the first bone fragment and causes a second portion of the bone device to contact the second bone fragment, the second portion different from the first portion; (b) wherein the bone device comprises a shape memory alloy having an austenite finish temperature; (c) creating in a responsive portion of the bone device at least a partial transformation into a stress-induced martensitic phase via stretching the responsive portion along the longitudinal axis; (d) after performing the stretching, fixing the second portion of the bone device to the second bone fragment; and (e) wherein the creating is performed at a temperature greater than the austenite finish temperature of the shape memory alloy. Dkt. No. 35-1 at 19 (col 12, lines 31-49) (alphabetic headings added for reference). The ’222 Patent also contains nine dependent claims. Id. at 19-20 (Claims 2 - 10). Based on these claims the parties have three disputes. First, they dispute the plain and ordinary meaning of “bone fragment” in claims 1, 3, 4, 7, and 8. Next, they dispute whether the “substantially in an austenitic phase” terms of claims 2, 7, and 8 are indefinite. Finally, they dispute whether specific steps of the method in claim 1 must be performed in a specific order. The Court addresses each dispute as follows. III. LEVEL OF ORDINARY SKILL IN THE ART It is well established that patents are interpreted from the perspective of one of ordinary skill in the art (“POSITA”). See Phillips, 415 F.3d at 1313 (“[T]he ordinary and customary meaning of a claim term is the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application.”). The Federal Circuit has advised that the “[f]actors that may be considered in determining the level of skill in the art include: (1) the educational level of the inventors; (2) the type of problems encountered in the art; (3) prior art solutions to those problems; (4) the rapidity with which innovations are made; (5) sophistication of the technology; and (6) education level of active workers in the field.” Env’tl Designs, Ltd. v. Union Oil Co.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Baran v. Medical Device Technologies, Inc.
616 F.3d 1309 (Federal Circuit, 2010)
Daiichi Sankyo Co., Ltd. v. Apotex, Inc.
501 F.3d 1254 (Federal Circuit, 2007)
Thorner v. Sony Computer Entertainment America LLC
669 F.3d 1362 (Federal Circuit, 2012)
Baldwin Graphic Systems, Inc. v. Siebert, Inc.
512 F.3d 1338 (Federal Circuit, 2008)
Ge Lighting Solutions, LLC v. Agilight, Inc.
750 F.3d 1304 (Federal Circuit, 2014)
Nautilus, Inc. v. Biosig Instruments, Inc.
134 S. Ct. 2120 (Supreme Court, 2014)
Golden Bridge Technology, Inc. v. Apple Inc.
758 F.3d 1362 (Federal Circuit, 2014)
Azure Networks, LLC v. Csr, Plc
771 F.3d 1336 (Federal Circuit, 2014)
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
789 F.3d 1335 (Federal Circuit, 2015)
Tecsec, Inc. v. Adobe Systems Incorporated
658 F. App'x 570 (Federal Circuit, 2016)
Basf Corporation v. Johnson Matthey Inc.
875 F.3d 1360 (Federal Circuit, 2017)
Cordis Corp. v. Medtronic Ave, Inc.
339 F.3d 1352 (Federal Circuit, 2003)
Dana Corp. v. American Axle & Manufacturing, Inc.
110 F. App'x 871 (Federal Circuit, 2004)
Vascular Solutions LLC v. Medtronic, Inc.
117 F.4th 1361 (Federal Circuit, 2024)

Cite This Page — Counsel Stack

Bluebook (online)
Medshape, Inc. v. Arthrex, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/medshape-inc-v-arthrex-inc-txwd-2025.